INIS
interleukins
100%
receptors
40%
infusion
31%
lymphocytes
31%
levels
27%
blood
18%
tantalum carbides
18%
in vivo
13%
patients
13%
in vitro
13%
molecules
9%
affinity
9%
humans
4%
clinical trials
4%
therapy
4%
tumor cells
4%
populations
4%
compartments
4%
concentration
4%
doses
4%
neoplasms
4%
enzymes
4%
steady-state conditions
4%
culture media
4%
lymphopenia
4%
tungsten carbides
4%
Medicine and Dentistry
Interleukin 2
63%
Interleukin 2 Receptor
36%
Infusion
31%
Serum
22%
Lymphocyte
22%
Blood
18%
In Vitro
13%
Clinical Trial
13%
Patient
9%
Cells
9%
Rebound
9%
Enzyme Linked Immunosorbent Assay
4%
Receptor
4%
Drug Megadose
4%
Combination Therapy
4%
Malignant Neoplasm
4%
Steady State
4%
Cytotoxicity
4%
Lymphocytopenia
4%
Target Cell
4%
Salicylate Sodium
4%
Peripheral Circulation
4%
Lymphocyte Subpopulation
4%
Lymphocytosis
4%
Lymphocyte Activation
4%
Tumor Cell Culture
4%
Culture
4%
Inpatient
4%
Therapeutic Procedure
4%
Biochemistry, Genetics and Molecular Biology
Interleukin 2
63%
Peripheral Blood Lymphocyte
13%
Molecule
9%
Rebound
9%
Blood Level
4%
Steady State
4%
Target Cell
4%
Lysozyme
4%
Cytotoxicity
4%
Peripheral Circulation
4%
Drug Megadose
4%
Lymphocyte Subpopulation
4%
Lymphocyte Activation
4%
Tumor Cell Culture
4%
Experiment
4%
Rose
4%
Neuroscience
Interleukin 2
63%
Interleukin 2 Receptor
36%
In Vivo
13%
In Vitro
13%
Eicosanoid Receptor
4%
Cytotoxicity
4%
Enzymes
4%
Lymphocyte Subpopulation
4%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 2
63%
Interleukin 2 Receptor
36%
Receptor
4%
Malignant Neoplasm
4%
Salicylate Sodium
4%
Lymphocytopenia
4%
Lymphocytosis
4%
Rose
4%